Skip to main content
. 2018 Jan 11;103(4):707–716. doi: 10.3324/haematol.2017.167486

Figure 6.

Figure 6.

Bortezomib affects primary multiple myeloma (MM) cells viability and functions within the scaffolds. (A) Primary MM cells from 6 patients were retrieved from scaffolds after 48 hours of bortezomib (BTZ) treatment; death was calculated as the percentage of CD38+/AnnV+ cells by flow cytometric analysis. (B) A representative experiment is shown. (C) Immunohistochemistry performed on scaffolds populated with primary MM cells from 2 patients reveals the presence of apoptotic MM cells upon bortezomib exposure, as indicated by both down-regulated CD138 expression and intense nuclear caspase-3 immunoreactivity. Bar=50 μm. (D) Metalloprotease (MMPs) activities are measured in supernatants from treated (BTZ) and untreated (NT) samples by zymography and densitometric analyses (left and middle panels). Results are mean±Standard Error of Mean (SEM) of 6 patients. Right panel shows a representative experiment. (E) Angiopoietin-2 (Ang-2), IL-6 and VEGF levels are determined in supernatants of treated and untreated scaffolds. Data are mean±SEM of 6 patients.*P≤ 0.05; **P≤ 0.01. a.u.: arbitrary units.